PurposeWhen emulating trials of medication initiation using real-world data, there may be ambiguity regarding the most suitable time zero event for the research question of interest. The time zero event must be strongly associated with the clinical indication for treatment, confer a reasonably high probability of actual treatment initiation, and be measurable with sufficient temporal precision in the source data. When it is uncertain whether a candidate event will satisfy these three conditions simultaneously, empirical identification of predictors of medication initiation can provide valuable guidance. The objective of this study was to empirically identify predictors of incident atorvastatin initiation to inform the definition of time zero for future target trial emulations.
MethodsA retrospective cohort study was conducted using Medicare claims data from January 1, 2018 - December 31, 2019 (study period). The study population included beneficiaries: age [≥] 65 years with [≥] 12 months of continuous enrollment and no statin medication for [≥] 12 months as of the study period start date. The index date was the date of the first pharmacy dispensing claim for a newly initiated medication during the study period, and classified as atorvastatin or non-atorvastatin (non-atorvastatin initiators randomly sampled at 10%). Candidate predictor variables were ascertained within 6 months pre-index and included demographics, comorbidities, healthcare utilization, and pharmacotherapy. A prespecified eight-step procedure was used to identify significant, independent predictors of incident atorvastatin initiation (vs initiating a medication other than atorvastatin).
Rowan, C. G. et al. · CC-BY 4.0